Physician profile
James Chang
NPI 1154422004
$513.84
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2023: $133 · 2024: $76.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $208.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $152.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $130.66 | 2023-2024 | Opdivo, Opdualag |
| Octapharma USA, INC. | $89.72 | 2019 | |
| Daiichi Sankyo INC. | $63.39 | 2019 | |
| Pharmaessentia USA Corporation | $19.51 | 2023 | Besremi |
| Astellas Pharma US INC | $16.31 | 2023 | Xtandi |
| Seagen INC. | $15.32 | 2023 | Adcetris |
| Pharmacyclics LLC, An Abbvie Company | $14.19 | 2023 | Imbruvica |
| Janssen Biotech, INC. | $12.74 | 2023 | Tecvayli, Talvey |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.